secwatch.observer — SEC 8-K summary
======================================

Issuer:     CNS Pharmaceuticals, Inc. (CNSP)
CIK:        0001729427
Form:       8-K
Filed at:   2023-10-18T23:59:59+00:00
Accession:  0001683168-23-007238
Event type: other
Sentiment:  neutral
Materiality: 0.20
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

CNS Pharmaceuticals posts investor video on Berubicin trial
-----------------------------------------------------------

- CEO John Climaco discusses Berubicin clinical trial in Virtual Investor event.
- Event link posted on October 18, 2023; no financial data or trial results disclosed in 8-K.
- No specific quantitative updates or forward guidance provided in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1729427/000168316823007238/0001683168-23-007238-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1729427/000168316823007238/cns_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-007238

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer